Administration of MCC950 determined a consistent decrease in the levels of IL-1β, TNF-α, IL-17A, IFN-γ, CCL20, CXCL1, IL-8 and IL-36γ from involved HS skin, with no significant change in the release of IL-1α, IL-18, IL-17C, MMP3 or S100A8. Here, IL17A is linked to histiocytic sarcoma.